| Literature DB >> 28164090 |
Abstract
In a number of cancers, deregulated MET pathway leads to aberrantly activated proliferative and invasive signaling programs that promote malignant transformation, cell motility and migration, angiogenesis, survival in hypoxia, and invasion. A better understanding of oncogenic MET signaling will help us to discover effective therapeutic approaches and to identify which tumors are likely to respond to MET-targeted cancer therapy. In this review, we will summarize the roles of MET signaling in cancer, with particular focus on epithelial-mesenchymal transition (EMT) and cancer stemness. Then, we will provide update on MET targeting agents and discuss the challenges that should be overcome for the development of an effective therapy.Entities:
Keywords: MET; cancer stem cell (CSC); epithelial-mesenchymal transition (EMT)
Year: 2017 PMID: 28164090 PMCID: PMC5253283 DOI: 10.21037/atm.2016.12.67
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839